A Lifetime Markov Model for the Economic Evaluation of Chronic Obstructive Pulmonary Disease

Author： Menn Petra   Leidl Reiner   Holle Rolf  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.30, Iss.9, 2012-09, pp. : 825-840

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The economic impact of chronic obstructive pulmonary disease

By Hilleman Daniel E   Faulkner Michele A  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 3, 2002-03 ,pp. : 219-228

Informa Healthcare

Access to resources Recommend Favorite

An Economic Overview of Chronic Obstructive Pulmonary Disease

By Ruchlin H.S.  

PharmacoEconomics, Vol. 19, Iss. 6, 2001-06 ,pp. : 623-642

Adis International

Access to resources Recommend Favorite

Evaluation of current pharmacotherapy of chronic obstructive pulmonary disease

By Culpitt S.V.   Rogers D.F.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 5, 2000-07 ,pp. : 1007-1020

Informa Healthcare

Access to resources Recommend Favorite

Levosalbutamol for chronic obstructive pulmonary disease: a treatment evaluation

By Patel Manish   Thomson Neil C  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 7, 2012-05 ,pp. : 1069-1075

Informa Healthcare

Access to resources Recommend Favorite

Development of an Economic Model to Assess the Cost Effectiveness of Treatment Interventions for Chronic Obstructive Pulmonary Disease

By Spencer Michael  

PharmacoEconomics, Vol. 23, Iss. 6, 2005-01 ,pp. : 619-637

Adis International

Access to resources Recommend Favorite